Siloam International Hospitals (SILO) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.042x

Based on the latest financial reports, Siloam International Hospitals (SILO) has a cash flow conversion efficiency ratio of 0.042x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp388.57 Billion ≈ $22.77 Million USD) by net assets (Rp9.25 Trillion ≈ $541.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Siloam International Hospitals defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Siloam International Hospitals - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Siloam International Hospitals's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Siloam International Hospitals Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Siloam International Hospitals ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Zhejiang DunAn Artificial Environment Co Ltd
SHE:002011
0.061x
PLUXEE NV
PA:PLX
0.434x
Novocure Ltd
NASDAQ:NVCR
-0.041x
Five-Star Business Finance Limited
NSE:FIVESTAR
0.002x
Sociedad Matriz SAAM SA
SN:SMSAAM
-0.031x
Mister Car Wash, Inc. Common Stock
NYSE:MCW
0.083x
Spartan Delta Corp
TO:SDE
0.139x
Hunan Kaimeite Gases Co Ltd
SHE:002549
0.034x

Annual Cash Flow Conversion Efficiency for Siloam International Hospitals (2010–2024)

The table below shows the annual cash flow conversion efficiency of Siloam International Hospitals from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Siloam International Hospitals (SILO) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Rp8.75 Trillion
≈ $512.81 Million
Rp2.33 Trillion
≈ $136.54 Million
0.266x +2.11%
2023-12-31 Rp8.05 Trillion
≈ $471.56 Million
Rp2.10 Trillion
≈ $122.96 Million
0.261x +22.99%
2022-12-31 Rp7.05 Trillion
≈ $413.19 Million
Rp1.50 Trillion
≈ $87.60 Million
0.212x -31.97%
2021-12-31 Rp6.52 Trillion
≈ $382.28 Million
Rp2.03 Trillion
≈ $119.13 Million
0.312x +40.32%
2020-12-31 Rp6.02 Trillion
≈ $352.65 Million
Rp1.34 Trillion
≈ $78.32 Million
0.222x +104.11%
2019-12-31 Rp5.99 Trillion
≈ $350.85 Million
Rp651.51 Billion
≈ $38.18 Million
0.109x +237.51%
2018-12-31 Rp6.32 Trillion
≈ $370.13 Million
Rp203.64 Billion
≈ $11.93 Million
0.032x -9.85%
2017-12-31 Rp6.31 Trillion
≈ $369.95 Million
Rp225.78 Billion
≈ $13.23 Million
0.036x -53.35%
2016-12-31 Rp3.13 Trillion
≈ $183.35 Million
Rp239.87 Billion
≈ $14.06 Million
0.077x -47.72%
2015-12-31 Rp1.74 Trillion
≈ $101.95 Million
Rp255.15 Billion
≈ $14.95 Million
0.147x -14.52%
2014-12-31 Rp1.65 Trillion
≈ $96.90 Million
Rp283.68 Billion
≈ $16.62 Million
0.172x +48.41%
2013-12-31 Rp1.64 Trillion
≈ $96.04 Million
Rp189.45 Billion
≈ $11.10 Million
0.116x -86.07%
2012-12-31 Rp244.64 Billion
≈ $14.33 Million
Rp203.01 Billion
≈ $11.90 Million
0.830x +177.97%
2011-12-31 Rp178.96 Billion
≈ $10.49 Million
Rp53.43 Billion
≈ $3.13 Million
0.299x -84.41%
2010-12-31 Rp137.58 Billion
≈ $8.06 Million
Rp263.40 Billion
≈ $15.43 Million
1.915x --

About Siloam International Hospitals

JK:SILO Indonesia Medical Care Facilities
Market Cap
$1.65 Billion
Rp28.18 Trillion IDR
Market Cap Rank
#6981 Global
#60 in Indonesia
Share Price
Rp2170.00
Change (1 day)
-3.13%
52-Week Range
Rp1845.00 - Rp2880.00
All Time High
Rp3750.00
About

PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID… Read more